Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas S Lin

Showing results (1-10 of 78) with videos related to

Pageof 8
Sort By:
Oncology (Williston Park, N.Y.)|February 6, 2008
What is the optimal initial treatment for chronic lymphocytic leukemia?Thomas S Lin
Clinical Lymphoma & Myeloma|November 1, 2008
Novel agents in chronic lymphocytic leukemia: efficacy and tolerability of new therapiesThomas S Lin
Current Hematologic Malignancy Reports|April 29, 2010
New agents in chronic lymphocytic leukemiaThomas S Lin
Pharmacogenomics and Personalized Medicine|December 11, 2012
Ofatumumab: a novel monoclonal anti-CD20 antibodyThomas S Lin
Current Hematology Reports|August 7, 2003
Autologous stem cell transplantation for non-Hodgkin's lymphomaThomas S Lin, Edward A Copelan
Seminars in Hematology|April 3, 2008
Antibody therapy for chronic lymphocytic leukemiaBeth A Christian, Thomas S Lin
Journal of Hematology & Oncology|July 22, 2009
Update in the management of chronic lymphocytic leukemiaKami J Maddocks, Thomas S Lin
Seminars in Oncology|April 18, 2006
Treatment of relapsed chronic lymphocytic leukemia: old and new therapiesJohn C Byrd, Thomas S Lin, Michael R Grever
Seminars in Oncology|August 27, 2003
Rituximab in B-cell chronic lymphocytic leukemiaThomas S Lin, Margaret S Lucas, John C Byrd
Clinical Lymphoma & Myeloma|September 26, 2009
Flavopiridol in chronic lymphocytic leukemia: a concise reviewBeth A Christian, Michael R Grever, John C Byrd, et al.
Pageof 8

Showing results (1-10 of 78) with videos related to

Sort By:
Pageof 8
Oncology (Williston Park, N.Y.)|February 6, 2008
What is the optimal initial treatment for chronic lymphocytic leukemia?Thomas S Lin
Clinical Lymphoma & Myeloma|November 1, 2008
Novel agents in chronic lymphocytic leukemia: efficacy and tolerability of new therapiesThomas S Lin
Current Hematologic Malignancy Reports|April 29, 2010
New agents in chronic lymphocytic leukemiaThomas S Lin
Pharmacogenomics and Personalized Medicine|December 11, 2012
Ofatumumab: a novel monoclonal anti-CD20 antibodyThomas S Lin
Current Hematology Reports|August 7, 2003
Autologous stem cell transplantation for non-Hodgkin's lymphomaThomas S Lin, Edward A Copelan
Seminars in Hematology|April 3, 2008
Antibody therapy for chronic lymphocytic leukemiaBeth A Christian, Thomas S Lin
Journal of Hematology & Oncology|July 22, 2009
Update in the management of chronic lymphocytic leukemiaKami J Maddocks, Thomas S Lin
Seminars in Oncology|April 18, 2006
Treatment of relapsed chronic lymphocytic leukemia: old and new therapiesJohn C Byrd, Thomas S Lin, Michael R Grever
Seminars in Oncology|August 27, 2003
Rituximab in B-cell chronic lymphocytic leukemiaThomas S Lin, Margaret S Lucas, John C Byrd
Clinical Lymphoma & Myeloma|September 26, 2009
Flavopiridol in chronic lymphocytic leukemia: a concise reviewBeth A Christian, Michael R Grever, John C Byrd, et al.
Pageof 8